Murine lymphoid cells were infected in vitro with WN 1802 B, a naturally occurring murine leukemia virus isolated from the spleen of an 18-month-old BALB/c mouse. Normal spleen and bone marrow cells were more susceptible to infection than were cells prepared from thymus and lymph node. Spleen cells from athymic nu/nu mice also could be readily infected with virus. Permissive MATERIALS AND METHODS Tissue Culture Lines. Viral growth was assayed in BALB/c mouse embryo fibroblasts (for B-tropic virus)t, NIH Swiss mouse embryo fibroblasts (for N-tropic virus)t, and SC-1 (for N-tropic and B-tropic virust) (6). SC-i and XC cells were obtained through the generosity of Drs. Janet Hartley and Wallace P. Rowe at the National Institutes of Health. All cell lines except SC-i were maintained in minimal essential medium with Earle's salts (MEM-E) supplemented with 10% heat-inactivated fetal calf serum, penicillin (50 units/ml), and streptomycin (50 ,tg/ml). SC-1 was maintained in McCoy's 5A medium supplemented with 10% heat-inactivated fetal calf serum and 1% penicillin-streptomycin-neomycin.
Murine leukemia virus (MuLV) has been implicated in the development of lymphoid tumors (1) . However, analysis of its oncogenicity has been hampered until recently by the absence of appropriate lymphocyte tissue culture systems. Rosenberg et al. (2) have effected transformation of fetal liver cells in vitro by Abelson leukemia virus in association with Moloney leukemia virus. The transformants express immunoglobulin determinants which suggests an origin from a primitive bone marrow-derived lymphocyte (B cell). A correlation between viral replication and the ability to transform a B cell precursor was observed which suggests that systems which are used to explore factors influencing replication of oncornaviruses can be expected to provide insight into malignant transformation. A similar relationship has been observed between the ability of radiation leukemia virus to infect thymocytes in vitro and induce thymomas in vivo (3) . Datta et al. (4) infected populations of spleen cells with virus obtained from AKR and B10.A lymphocytes and observed that cells activated in the mixed leukocyte reaction supported more viral replication than normal cells.
We report here the results of experiments designed to identify the host cell for another strain of MuLV and to define conditions which influence permissivity in this system. Our interest derives in part from the observation that MuLV titer is correlated with the development of lymphoreticular tumors associated with the graft versus host reaction (5) . Our results indicate that the bone marrow-derived lymphocyte is the cell which can be infected most readily in vitro by WN 1802 B, a naturally occurring MuLV. Viral replication is considerably enhanced when cells are activated by the B cell mitogen, lipopolysaccharide.
MATERIALS AND METHODS
Tissue Culture Lines. Viral growth was assayed in BALB/c mouse embryo fibroblasts (for B-tropic virus)t, NIH Swiss mouse embryo fibroblasts (for N-tropic virus)t, and SC-1 (for N-tropic and B-tropic virust) (6) . SC-i and XC cells were obtained through the generosity of Drs. Janet Hartley and Wallace P. Rowe at the National Institutes of Health. All cell lines except SC-i were maintained in minimal essential medium with Earle's salts (MEM-E) supplemented with 10% heat-inactivated fetal calf serum, penicillin (50 units/ml), and streptomycin (50 ,tg/ml). SC-1 was maintained in McCoy's 5A medium supplemented with 10% heat-inactivated fetal calf serum and 1% penicillin-streptomycin-neomycin.
Virus. Murine leukemia virus WN 1802 B, pool 1897, was used. This is a naturally occurring B-tropic virus isolated from the spleen of an 18-month-old BALB/c mouse by Hartley and Rowe (7) . The virus was maintained through infection of BALB/c fibroblasts in tissue culture.
Virus Assay. The UVXC test for ecotropic MuLV developed by Rowe, Pugh, and Hartley (8) , and performed routinely in our laboratory as described previously (5) , was used to assay virus solutions or lymphoid cells which contained virus.
Preparation of Lymphoid Cell Cultures. Cells from BALB/cN and (BALB/cJ X A/J) F1 (CAF1) mice 2 to 4 months of age were used. Both strains are of the Fv-1 bb genotype whose fibroblasts support B-tropic virus replication. These mice were obtained from Jackson Laboratory, Bar Harbor, Maine, or from a colony maintained at Yale University. BALB/c nu/nu mice were obtained from ARS Sprague-Dawley. Spleen, thymus, and lymph node cells were prepared as described previously (9) . For preparation of bone marrow cells, the ends of femurs and humeri were cut and the marrow flushed out by use of Hanks' balanced salt solution (HBSS), with a 27-gauge needle on a 1 ml tuberculin syringe. Clumps were dispersed with gentle pipetting. Medium RPMI 1640 supplemented with L-glutamine (2 mM), antibiotic-antimycotic solution (penicillin 100 units/ml, fungizone 0.25 ug/ml, and streptomycin 100 ttg/ml) and 5% heat-inactivated fetal calf serum was used. Nucleated cells (2 X 106) were dispensed in 1 ml cultures in 16 X 100 mm culture tubes (Falcon Plastics). Mitogen solutions included were phytohemagglutinin (PHA) 18 ,gg/ml, concanavalin A (Con A) 5 ,gg/ml, and bacterial lipopolysaccharide (LPS) 10,gg/ml. They were obtained from Difco, Calbiochem, and Difco, respectively. Cultures were incubated at 370 in a humidified atmoi The terms N-tropic and B-tropic as used here are concerned with the genotype of the murine fibroblast which supports replication of a particular virus (6) . N The stimulatory effects of the B cell mitogen and the inhibitory effect of T cell mitogens on viral replication are probably mediated through an effect on the host cell rather than through a direct effect on the virus, because mitogen was no longer present in large quantities at the time of viral addition as the medium was replaced or treated with inhibitors. Furthermore, when fibroblasts were treated with LPS or PHA, no effect on exogenous MuLV replication was seen (Table 2) .
A series of experiments performed to investigate the effects of LPS, PHA, and another T cell mitogen, Con A, on both DNA synthesis and WN 1802 B replication are summarized in Table  3 . Results of four experiments in which LPS-treated spleen cells were exposed to exogenous MuLV are presented. In three experiments, B-tropic MuLV Cell cultures of BALB/c spleen and lymph node were established with and without mitogen. After 48 hr, medium was removed, 0.3 ml of WN 1802 B (0.004 PFU/cell, Exp. 1 and 0.001 PFU/cell, Exp. 3) was added; virus was absorbed to cells for 1 hr, and then an additional 0.6 ml medium was added. Control cultures that received no exogenous MuLV were also maintained. Four days later, the lymphoid cells were tested for release of endogenous MuLV, and replication of the added WN 1802 B as in the legend accompanying Fig. 1 Release of endogenous ecotropic virus was not stimulated after mitogen treatment in any of the experiments depicted in Tables 2 and 3 , nor in several additional experiments: seven in which spleen or lymph node cells were treated with LPS, sixteen with PHA, five with Con A, and seven mixed leukocyte reactions. Of 52 experiments, 47 were negative for MuLV release. In the remaining five cell preparations, there were never more than two plaques of endogenous MuLV, whether or not the cells were treated with mitogen. Though another group has reported activation of XC detectable MuLV in the mixed leukocyte reaction (10), others have not observed ecotropic virus in lymphocytes stimulated by the mixed leukocyte reaction (11) or LPS (12) with the reverse transcriptase assay. However, they did note an increase in enzyme activity due to xenotropic virus (which would not be scored with the XC test). them. The bulk of virus replication occurred in cells which were nonadherent and nonphagocytic. DISCUSSION Evidence has been presented that WN 1802 B, an isolate of murine leukemia virus from a BALB/c mouse, is capable of replicating in lymphoid cells in vitro. Though we have not as yet precisely identified the permissive cell on the basis of surface antigen markers, we infer that it is the bone marrow-derived lymphocyte. This conclusion is based on four types of evidence: (i) replication of exogenous WN 1802 B is stimulated in cells treated with LPS, a B cell mitogen, and is inhibited in cells treated with T cell mitogens, PHA and Con A; (0i) spleen cells from nu/nu mice, which lack T cells support WN 1802 B replication; (iii) an organ distribution analysis indicates that cells which can be infected by MuLV are found in high concentrations in bone marrow and spleen (which have correspondingly high concentrations of B cells) and in lower concentrations in thymus and lymph node (with higher proportions of T cells); (iv) the virus preferentially infects nonadherent and nonphagocytic cells.
The mechanism by which LPS stimulates WN 1802 B replication in spleen and lymph node cells must be due in part to its mitogenic effect, because it has been amply demonstrated that DNA synthesis is required for MuLV replication in fibroblasts (13) . Our experiments demonstrate, however, that mere stimulation of DNA synthesis is not sufficient because T cells stimulated with PHA, Con A, or specific antigen (N. Ruddle, in preparation) were not more permissive than normal cells. This suggests that preferential infection of a particular cell must occur before replication proceeds.
The inhibition of WN 1802 B replication in lymphoid cells treated with the T cell mitogens, PHA, and Con A is currently under investigation. One possibility is that interferon is produced by stimulated T cells which inhibits MuLV replication (14) ; another possibility is that PHA stimulates a population of cells which can bind virus but not replicate it, in-effect diluting the virus concentration for the permissive B cell. It is unlikely that PHA and Con A are inhibiting MuLV by binding virus, a mechanism which could be inferred from the recent report of Ishizaki and Bolognesi (15) . These authors observed inhibition of Rous sarcoma virus infection of fibroblasts after virus was mixed with lectin at concentrations 50 to 200 times greater than those used to stimulate cells in the experiments reported here.
Stimulation of virus replication in lymphoid cells after mitogen treatment was first described by Wheelock et al. (16) . It has become apparent that each animal virus exhibits a tropism for a particular lymphocyte cell type. For example, viruses which replicate in T cells include vesicular stomatitis virus (17) and herpes-saimiri virus (18) , whereas B cells are infected by Epstein-Barr virus (19) , cytomegalovirus (20) , and the naturally occurring murine leukemia virus, WN 1802 B. Cerny has also reported that Friend leukemia virus is associated with B memory cells in VIvo (21) , and replicates in LPS stimulated cells in vitro (22) . It will be interesting to determine whether other types of murine leukemia viruses will preferentially replicate in T cells in vitro. Haas and Hilgers (3) have demonstrated that thymocytes can be infected by radiation leukemia virus but did not determine whether replication could be enhanced in stimulated T cells.
The studies reported here have broad implications for the understanding of certain types of malignancy, because stimulation of a lymphoid cell by an agent as innocuous as a bacterial cell wall component can markedly enhance its ability to be infected by an oncogenic virus. Such a mechanism may be operative in two systems in which tumor development is associated with lymphocyte stimulation-the increased incidence of lymphoreticular tumors associated with activation of MuLV in the course of the graft versus host reaction in mice (5), and the increased incidence of lymphoid malignancies associated with the chronic immunological stimulus of the kidney transplant (23) .
